Januvia (Sitagliptin) has been approved by the European Commission

Shares

According to Diabetes UK the European Commission has approved Sitagliptin ,known as Januvia, as an add-on to insulin (with or without metformin) for people with type 2 diabetes. Most type 2 diabetics can control their condition with a combination of diet, physical activity and conventional medication. Januvia was approved by the FDA in 2006 and has shown good results in type 2 diabetics.

Januvia is an oral medication for management of type 2 diabetes only. It’s the first in a class of drugs called DPP-4 inhibitors. Januvia lowers blood sugar levels by blocking an enzyme known as dipeptidyl peptidase IV or DPP-4. DPP-4 is responsible for breaking down the proteins that stimulate the insulin producing cells after a meal. If DPP-4 is inhibited, then the proteins can activate the release of insulin for a longer period of time, thereby lowering the glucose level in the blood.

Leave a Reply

avatar
3000
  Subscribe  
Notify of
Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.